The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

DUBLIN, Apr. 03, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/gw6znv/the_engineered) has announced the addition of the "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" report to their offering.

(Logo:http://photos.prnewswire.com/prnh/20130307/600769)

A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective

Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.

Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.

The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.

This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.

Benefits from the report:

• Identify players in the field, from industry and academia;
• Find out which TCR technologies are valued by Big Pharma and Biotech;
• Understand the value of intracellular antigens targeted by the TCR;
• Recognize the challenges of TCR-based therapeutics and their solutions;
• Learn which TCR-based therapeutics are attractive for partnering;
• Find out which TCR therapeutic approaches are not yet tapped.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. The T-Cell Receptor

4. TCR Fusion Proteins

5. TCR-Like (TCRL) Antibodies

6. TCR-Transfected T-Cells

7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells

8. Tumor-Infiltrating Lymphocytes (TILs)

9. Opportunity Analysis for TCR-based Products and Technologies

10. References

11. Corporate R&D Pipelines


Companies Mentioned:

• Adaptimmune
• Altor Bioscience
• Immunocore
• Lion Biotechnologies

For more information visit http://www.researchandmarkets.com/research/gw6znv/the_engineered

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net